VAXNEUVANCE April 2026
SELECTED SAFETY INFORMATION
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
VAXNEUVANCE is not listed on the National Immunisation Program.
Before prescribing, please review the Product Information available at www.msdinfo.com.au/vaxneuvancepi.
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at
www.tga.gov.au/reporting-problems.
INDICATION
VAXNEUVANCE is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults and children from 6 weeks of age1. VAXNEUVANCE may not prevent disease caused by Streptococcus pneumoniae serotypes that are not contained in the vaccine.
The use of VAXNEUVANCE should be guided by official recommendations.1
SELECTED SAFETY INFORMATION
CONTRAINDICATIONS: Individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or any diphtheria toxoid-containing vaccine.1
PRECAUTIONS: Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE. The potential risk of apnoea should be considered when administering to infants born prematurely – as the benefit of vaccination is high in this group of infants, vaccination generally should not be withheld or delayed. As with any vaccine, VAXNEUVANCE may not protect all vaccine recipients. The safety and effectiveness of VAXNEUVANCE in children younger than 6 weeks of age have not been established. Pregnancy category B1.1
ADVERSE EFFECTS: Children: Pain, erythema, swelling, induration, decreased appetite, irritability, somnolence, urticaria, elevated body temperature, fatigue, headache, myalgia, injection-site urticaria. Adults: Pain, erythema, swelling, fatigue, headache, myalgia, arthralgia, elevated body temperature, injection site pruritus.1
Reference: 1. VAXNEUVANCE Australian Approved Product Information, 31 October 2024.
AU-PVC-00090 v2. Issued April 2026.
VAXNEUVANCE is not listed on the National Immunisation Program.
Before prescribing, please review the Product Information available at www.msdinfo.com.au/vaxneuvancepi.
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at
www.tga.gov.au/reporting-problems.
INDICATION
VAXNEUVANCE is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults and children from 6 weeks of age1. VAXNEUVANCE may not prevent disease caused by Streptococcus pneumoniae serotypes that are not contained in the vaccine.
The use of VAXNEUVANCE should be guided by official recommendations.1
SELECTED SAFETY INFORMATION
CONTRAINDICATIONS: Individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or any diphtheria toxoid-containing vaccine.1
PRECAUTIONS: Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE. The potential risk of apnoea should be considered when administering to infants born prematurely – as the benefit of vaccination is high in this group of infants, vaccination generally should not be withheld or delayed. As with any vaccine, VAXNEUVANCE may not protect all vaccine recipients. The safety and effectiveness of VAXNEUVANCE in children younger than 6 weeks of age have not been established. Pregnancy category B1.1
ADVERSE EFFECTS: Children: Pain, erythema, swelling, induration, decreased appetite, irritability, somnolence, urticaria, elevated body temperature, fatigue, headache, myalgia, injection-site urticaria. Adults: Pain, erythema, swelling, fatigue, headache, myalgia, arthralgia, elevated body temperature, injection site pruritus.1
Reference: 1. VAXNEUVANCE Australian Approved Product Information, 31 October 2024.
AU-PVC-00090 v2. Issued April 2026.